title: Pretreatment of mice with rifampicin prolongs survival of endotoxic shock by modulating the levels of inflammatory cytokines.
abstract: To investigate the effects of rifampicin in a mouse model of endotoxin shock, mice were pretreated with rifampicin for at different times before and after challenging with a lethal dose of lipopolysaccharide (LPS). We found that rifampicin had a significant preventive effect and reduced the mortality of mice at early stages. To further understand the mechanism, plasma cytokine levels were examined. Mice treated with LPS alone showed markedly increased plasma levels of TNF, IL-1beta, IL-6, and IL-10, while mice pretreated with rifampicin showed significantly lower plasma levels of these cytokines compared to the LPS alone. Our results suggest that rifampicin has a beneficial effect on septic shock caused by LPS through modulation of cytokines. This suggests that rifampicin could be a candidate for treatment of septicemia caused by gram-negative bacterial infection.
authors.affiliation: Department of Veterinary Pharmacology, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, People's Republic of China.
authors.forename: Na
authors.initials: N
authors.lastname: An
authors.forename: Yu
authors.initials: Y
authors.lastname: Song
authors.forename: Xuemei
authors.initials: X
authors.lastname: Zhang
authors.forename: Xinxin
authors.initials: X
authors.lastname: Ci
authors.forename: Hongyu
authors.initials: H
authors.lastname: Li
authors.forename: Yongguo
authors.initials: Y
authors.lastname: Cao
authors.forename: Mohan
authors.initials: M
authors.lastname: Zhang
authors.forename: Junqing
authors.initials: J
authors.lastname: Cui
authors.forename: Xuming
authors.initials: X
authors.lastname: Deng
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000097:blood*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D018836:Inflammation Mediators / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides; D051379:Mice; D008810:Mice, Inbred C57BL; D012293:Rifampin / Q000008:administration & dosage*; D012772:Shock, Septic / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D012293:Rifampin